RxDoctor Payments Data

Steven Dennis, MD

Family Medicine · Houston, TXNPI 1811011869

Payments from drug & device makers

$8,992in general payments, 2019–2025

Across 546 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$2K
  • Novo Nordisk$1K
  • GSK$716
  • AstraZeneca$657
  • Amgen$624
  • Esperion Therapeutics, Inc.$501
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,89799%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,992 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$52,755
Medicare patients
202
Services billed
805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$90,643
MounjaroTirzepatide50$56,154
JardianceEmpagliflozin28$32,836
Janumet XrSitagliptin Phos/Metformin Hcl14$20,958
EliquisApixaban24$17,145
TrulicityDulaglutide12$13,111
Synjardy XrEmpagliflozin/Metformin Hcl13$12,317
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid17$5,057
Atorvastatin Calcium219$2,585
Metoprolol Succinate142$2,163
Tamsulosin Hcl119$2,082
Olmesartan Medoxomil74$2,045
Rosuvastatin Calcium106$1,703
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide51$1,518
Levothyroxine Sodium149$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,163$90,64360 claims
Lilly USA, LLCMounjaro, Trulicity$405$69,26562 claims
Boehringer IngelheimJardiance, Synjardy Xr$244$45,15341 claims
MerckJanumet Xr$151$20,95814 claims
PfizerEliquis$208$17,14524 claims
AbbVieSynthroid$402$1,08033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →